• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Adjunctive glucose-lower therapies do not decrease risk of microvascular complications in diabetic patients

byBryant LimandKiera Liblik
September 23, 2022
in Cardiology, Chronic Disease, Endocrinology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. No significant differences in vascular complications of diabetes were seen in patients using metformin and adjunctive glargine, liraglutide, glimepiride, or sitagliptin treatment.

2. Adjunctive liraglutide treatment resulted in a small but significant difference in the rate of any cardiovascular disease.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Micro- and macrovascular complications of diabetes mellitus are associated with significant debilitation and healthcare costs. Clinical trials have shown vascular protective effects of new classes of glucose-lowering medication, such as insulin glargine, the sulfonylurea glimepiride, the glucagon-like peptide-1 receptor agonist liraglutide, and the dipeptidyl-peptidase 4 inhibitor sitagliptin. Previous work has shown that metformin with adjunctive glargine and liraglutide is more effective than adjunctive glimepiride and sitagliptin in maintaining glycemic targets. The present study describes secondary outcomes, evaluating the incidence of micro- and macrovascular events. Adult patients with a diagnosis of type two diabetes were randomized to receive one of four treatments (glargine, glimepiride, liraglutide, or sitagliptin) in addition to metformin. There were no significant differences between groups in the incidence of new hypertension or dyslipidemia development. For microvascular outcomes, there were no significant differences in the incidence of renal impairment or diabetic peripheral neuropathy. For cardiovascular outcomes, the liraglutide group had fewer cases of any cardiovascular event compared to the other three treatment groups. The rates of hospitalization and deaths due to cardiovascular events were not different between groups. As a limitation, patients with a history of a major cardiovascular event or renal impairment were excluded from the study, which reduces the generalizability of the results to a population with more advanced diabetes.

Click to read the study in NEJM

In-Depth [randomized controlled trial]: This study reports the secondary outcomes of the incidences of microvascular and cardiovascular complications from a randomized control trial that evaluated the efficacy of metformin with adjunctive glargine, glimepiride, liraglutide, or sitagliptin in patients with type two diabetes. Adult patients with type two diabetes (n = 5,047) were randomly assigned to receive one of the four treatments in addition to metformin. Treatment dosages were determined based on drug labeling. Patients were followed for a mean of 5.0 years. Baseline prevalence of hypertension (77%), dyslipidemia (96%), diabetic peripheral neuropathy (42%), and history of heart attack or stroke (6.4%) reflected the general United States population. There were no significant differences in new hypertension or dyslipidemia cases between groups. For microvascular outcomes, there were no differences among treatment groups in the incidence of moderately or severely increased albuminuria levels or renal impairment, as defined by the estimated glomerular filtration rate. There were no significant differences in the incidence of diabetic peripheral neuropathy. For cardiovascular outcomes, the liraglutide group had the fewest cases of cardiovascular event [(liraglutide compared to sitagliptin group: Hazard Ratio [HR], 0.68; 95% Confidence Interval [CI], 0.51 to 0.90) and (liraglutide compared to glimepiride group: HR, 0.71; 95% CI, 0.53 to 0.93)]. The incidences of cardiovascular-related hospitalizations and deaths were not significantly different between groups. In summary, while the four groups showed significant differences in glycemic control in the primary outcome analysis reported elsewhere, there were no associated differences between groups in micro- and cardiovascular outcomes.

RELATED REPORTS

2 Minute Medicine Rewind June 23, 2025

Repeated medial branch blocks do not improve pain outcomes for thermal radiofrequency ablation

Artificial intelligence may assist in early detection of decreased ejection fraction on echocardiograms

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: cardiologychronic diseasediabetesdiabetes mellitusendocrinologyglargineglimepirideliraglutidemetforminsitagliptintype 2 diabetes
Previous Post

Aerobic and strengthening physical activity may have a dose-response association with mortality

Next Post

Factors associated with anticoagulation discontinuation in palliative care patients

RelatedReports

Weekly Rewinds

2 Minute Medicine Rewind June 23, 2025

June 23, 2025
High incidence of foreskin morbidity in uncircumcised males
Cardiology

Repeated medial branch blocks do not improve pain outcomes for thermal radiofrequency ablation

June 21, 2025
Lisinopril and carvedilol reduce cardiotoxicity in breast cancer patients receiving trastuzumab and anthracyclines
Cardiology

Artificial intelligence may assist in early detection of decreased ejection fraction on echocardiograms

June 19, 2025
Survival greater in cervical cancer patients undergoing abdominal hysterectomy compared to minimally invasive techniques: the LACC trial
Weekly Rewinds

2 Minute Medicine Rewind June 16, 2025

June 16, 2025
Next Post

Factors associated with anticoagulation discontinuation in palliative care patients

Quick Take: Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent)

Roflumilast cream superior to vehicle cream in the treatment of plaque psoriasis – the DERMIS-1 and DERMIS-2 trials

Colchicine may lower the risk of cardiovascular events in patients with coronary disease

2 Minute Medicine Rewind September 26, 2022

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
  • 2 Minute Medicine Rewind June 23, 2025
  • Reductions in pain catastrophizing are associated with improvements in emotional functioning
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.